Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 2/20 | 0.34 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.30 |
| ▸ | CD44 | P16070 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21936671 | 0.81 | HTR2C (0.36) | BRD4CREBBPHTR2C | |
| SCHEMBL24343563 | 0.77 | — | — | |
| SCHEMBL9905053 | 0.77 | BRD4 (0.35) | BRD4CREBBPHTR2CTRPA1CD44 | |
| SCHEMBL30065639 | 0.77 | BRD4 (0.35) | BRD4CREBBPHTR2CTRPA1CD44 | |
| SCHEMBL22827426 | 0.77 | PDK2 (0.37) | KRASSOS1PDK2 | |
| SCHEMBL23995719 | 0.77 | PTGS2 (0.40) | — | |
| SCHEMBL23344916 | 0.77 | SOS1 (0.41) | KRASSOS1HTR2CCYP1A2 | |
| SCHEMBL25020196 | 0.77 | BACE1 (0.36) | PDK2 | |
| SCHEMBL25020192 | 0.77 | KRAS (0.30) | KRASSOS1 | |
| SCHEMBL8738261 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-11-16 | — | — | US | disclosed |
| US-11814380-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-11-14 | — | — | US | disclosed |
| US-11814380-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-11-14 | — | — | US | disclosed |
| US-20230348424-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | SCHRÖDINGER, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348424-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | SCHRÖDINGER, INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2023150291-A2 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | SCHRÖDINGER, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023125737-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF | SILEXON AI TECHNOLOGY CO., LTD. (CN) | 2023-07-06 | — | — | WO | disclosed |
| EP-3728254-B1 | BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-02-15 | — | — | EP | disclosed |
| US-20230029385-A1 | 2-METHYL-AZA-QUINAZOLINES | BAYER AG (DE) | 2023-01-26 | — | — | US | disclosed |
| WO-2023287730-A1 | TRICYCLIC COMPOUNDS | RECURIUM IP HOLDINGS, LLC (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2022271679-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022081912-A2 | HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2021074227-A1 | 2-METHYL-AZA-QUINAZOLINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-22 | — | — | WO | disclosed |
| US-20210009588-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-01-14 | — | — | US | disclosed |
| US-10829487-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-11-10 | — | — | US | disclosed |
| US-20190194192-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009588-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | SOS1, SOST, SOS2 | KRAS 187/4885SOS1 1/4885BRD4 2354/4885 |
| US-20230029385-A1 | 2-METHYL-AZA-QUINAZOLINES | AZI2, DNMT1, TPMT | KRAS 145/4885SOS1 2630/4885BRD4 457/4885 |
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | KRAS 14/4885SOS1 2/4885BRD4 3726/4885 |
| US-20230348424-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | APC, RCC2, CDC37 | KRAS 158/4885SOS1 3170/4885BRD4 1287/4885 |
| US-11814380-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | SOS1, SOST, BMP1 | KRAS 273/4885SOS1 1/4885BRD4 2165/4885 |
| US-20190194192-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | SOS1, SOST, SOS2 | KRAS 185/4885SOS1 1/4885BRD4 2334/4885 |
| US-10829487-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | SOS1, SOST, BMP1 | KRAS 272/4885SOS1 1/4885BRD4 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.